Candel Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CAN-3110 -- a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate ? for the treatment of patients with recurrent high-grade glioma (HGG) to improve overall survival.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 USD | -9.45% | +23.39% | +682.31% |
04-11 | Sector Update: Health Care Stocks Decline Thursday Afternoon | MT |
04-11 | Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+682.31% | 337M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- CADL Stock
- News Candel Therapeutics, Inc.
- Candel Therapeutics, Inc.'s CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma